Genomic Cancer Panel & Profiling Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Tissue Testing (Solid Tissue Testing, Liquid Tissue Testing), By Cancer Panel Type (Single-Gene Panel, Multi-Gene Panel), By Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, Prostate Cancer, Others), By Application (Clinical, Research), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others), By End-User (Hospitals, Clinical and Diagnostic Laboratories, Others), By Region and Competition, 2019-2029F
Global Genomic Cancer Panel & Profiling Market was valued at USD 9.95 billion in 2023 and is anticipated t%li%project steady growth in the forecast period with a CAGR of 9.43% through 2029. The Global Genomic Cancer Panel & Profiling Market is undergoing remarkable growth and transformation, driven by advancements in precision medicine and genomic technologies. This market revolves around the thorough analysis of cancer-related genomic alterations t%li%guide personalized treatment strategies. Genomic cancer panels, which consist of sets of genes associated with various cancer types, empower clinicians t%li%pinpoint specific mutations, copy number variations, and other genetic abnormalities within a patient's tumor. This information is pivotal for tailoring therapies, predicting treatment responses, and comprehending the genetic underpinnings of cancer. Next-Generation Sequencing (NGS) technologies are instrumental, allowing for high-throughput and detailed genomic profiling. The market's expansion is spurred by the escalating global cancer incidence, underscoring the necessity for precise diagnostic tools.
The incorporation of artificial intelligence and machine learning augments the interpretation of intricate genomic data, facilitating more precise and expedited insights. Collaborations between biotechnology firms and research institutions drive innovation and the creation of comprehensive genomic profiling solutions. These partnerships advance the comprehension of cancer biology and aid in identifying novel therapeutic targets. The market witnesses a shift towards liquid biopsy approaches, enabling non-invasive and real-time monitoring of cancer-related genetic alterations. Liquid biopsy techniques, such as the examination of circulating tumor DNA (ctDNA), contribute t%li%early detection, treatment monitoring, and the evaluation of minimal residual disease.
Furthermore, the trend towards multi-omic integration, which merges genomic data with transcriptomics, proteomics, and other -omics information, offers a holistic perspective of cancer biology. This integrated approach enhances the identification of biomarkers and potential therapeutic targets, fostering a more thorough understanding of the complex molecular mechanisms underlying different cancer types. As the global healthcare landscape increasingly prioritizes personalized and targeted therapies, the Genomic Cancer Panel & Profiling Market is poised for further growth, delivering innovative solutions for precise cancer diagnostics and treatment decision-making. The continuous evolution of genomic technologies and their applications underscores the market's dynamic nature in advancing the era of personalized oncology.
Key Market Drivers
Advancements in Genomic Technologies
Advancements in genomic technologies have been instrumental in shaping the landscape of the Global Genomic Cancer Panel & Profiling Market, ushering in a new era of precision medicine. Next-Generation Sequencing (NGS) stands as a cornerstone in these advancements, revolutionizing the speed, efficiency, and depth of genomic analysis. The continuous evolution of NGS platforms has enabled researchers and clinicians t%li%conduct comprehensive genomic profiling with unprecedented accuracy and scale. Improved sequencing speed and reduced costs have made genomic profiling more accessible, allowing for the analysis of a broader range of genes and facilitating a deeper understanding of cancer-related genetic alterations. Beyond NGS, other genomic technologies such as microarray-based platforms and digital PCR contribute valuable insights. Microarrays provide a high-throughput method for simultaneously examining the expression levels of multiple genes, aiding in the identification of biomarkers associated with specific cancers.
Digital PCR offers enhanced sensitivity in detecting rare genetic mutations, contributing t%li%the precision of genomic profiling. The integration of artificial intelligence (AI) and machine learning (ML) has emerged as a transformative force in genomic data interpretation. Advanced algorithms analyze vast datasets, helping identify patterns, predict treatment responses, and discover novel genetic markers. This fusion of genomic technologies and AI not only accelerates the analysis process but als%li%enhances the accuracy of identifying clinically relevant genomic alterations. The advent of single-cell genomics represents another breakthrough, allowing researchers t%li%analyze individual cells within a heterogeneous tumor. This technology unveils the intra-tumor heterogeneity and provides a more nuanced understanding of the genetic diversity present in cancers. These collective advancements empower the Genomic Cancer Panel & Profiling Market t%li%offer more comprehensive and precise insights int%li%the genomic landscape of cancers. As these technologies continue t%li%evolve, the market is poised t%li%witness further refinement in diagnostic accuracy, therapeutic decision-making, and the realization of personalized treatment strategies for cancer patients globally.
Rising Cancer Incidence
The Global Genomic Cancer Panel & Profiling Market is significantly influenced by the alarming and escalating incidence of cancer worldwide. The pervasive rise in cancer cases serves as a driving force behind the increasing adoption of genomic technologies for comprehensive cancer profiling. Cancer remains a leading cause of morbidity and mortality globally, with new cases diagnosed each year reaching staggering numbers. This surge in cancer incidence intensifies the need for precise diagnostic tools that can unravel the intricate genetic underpinnings of various cancer types. Genomic cancer panels play a pivotal role in this scenari%li%by offering a systematic approach t%li%analyze the genetic alterations associated with specific cancers. As the diversity of cancer types expands, s%li%does the demand for tailored genomic profiling solutions. The ability of genomic technologies, such as Next-Generation Sequencing (NGS), t%li%analyze a multitude of genes simultaneously provides clinicians with a comprehensive view of the genomic landscape, aiding in the identification of key mutations, copy number variations, and other genetic abnormalities driving cancer progression.
The rising cancer incidence not only emphasizes the urgency for accurate and early diagnosis but als%li%underscores the importance of personalized treatment strategies. Genomic profiling enables clinicians t%li%identify specific genetic markers that guide the selection of targeted therapies, contributing t%li%more effective and tailored interventions. The exploration of new and emerging biomarkers associated with different cancer types is fueled by the need t%li%understand the molecular intricacies of each case, further amplifying the relevance and demand for genomic cancer panels. In conclusion, the relentless increase in cancer incidence acts as a catalyst for the Global Genomic Cancer Panel & Profiling Market, driving advancements in genomic technologies and fostering a paradigm shift towards precision medicine in the fight against cancer.
Precision Medicine Initiatives
Precision medicine initiatives are playing a pivotal role in shaping the trajectory of the Global Genomic Cancer Panel & Profiling Market, ushering in an era of personalized and targeted therapeutic approaches. These initiatives are driven by the recognition that each patient's cancer is unique, necessitating tailored treatment strategies based on the individual's genetic makeup. Genomic cancer panels stand at the forefront of this paradigm shift, enabling comprehensive analysis of the molecular alterations within a patient's tumor. The core principle of precision medicine is t%li%match specific genomic aberrations with targeted therapies, optimizing treatment outcomes and minimizing adverse effects. As genomic technologies, particularly Next-Generation Sequencing (NGS), become more sophisticated and accessible, precision medicine initiatives gain momentum. Clinicians leverage genomic cancer panels t%li%identify key genetic mutations, copy number variations, and other alterations that drive cancer progression.
This information becomes crucial for making informed decisions about the most effective therapies for a particular patient. These initiatives are often part of large-scale collaborative efforts involving healthcare institutions, research organizations, and biotechnology companies. The goal is t%li%create extensive databases of genomic and clinical data, facilitating a deeper understanding of the genetic basis of cancer and refining treatment strategies. The integration of artificial intelligence and machine learning further enhances the interpretation of vast datasets, assisting clinicians in identifying relevant biomarkers and predicting treatment responses. Precision medicine initiatives contribute t%li%the shift from a one-size-fits-all approach t%li%cancer treatment t%li%a more nuanced and individualized methodology. By aligning treatment plans with the specific genomic profile of each patient's cancer, these initiatives not only improve therapeutic efficacy but als%li%pave the way for future advancements in oncology. The Global Genomic Cancer Panel & Profiling Market is intricately linked t%li%the success and expansion of precision medicine initiatives, as they collectively drive innovation and bring about transformative changes in cancer care.
Key Market Challenges
Data Privacy and Security Concerns
Data privacy and security concerns constitute significant challenges within the Global Genomic Cancer Panel & Profiling Market. The extensive generation, storage, and sharing of genomic data raise crucial issues regarding patient confidentiality and protection. Genomic information is inherently sensitive, encompassing an individual's unique genetic makeup and potential predispositions t%li%various health conditions, including cancer. Securing genomic data from unauthorized access, breaches, or misuse is paramount. The fear of data breaches and the potential misuse of this highly personal information contribute t%li%concerns among patients, healthcare providers, and regulatory bodies.
The need t%li%comply with stringent data protection regulations, such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States or the General Data Protection Regulation (GDPR) in Europe, adds an additional layer of complexity. The challenge lies in establishing robust and standardized security measures t%li%safeguard genomic data throughout its lifecycle—from collection and storage t%li%transmission and analysis. Implementing encryption, access controls, and secure data sharing protocols becomes essential. Striking a balance between facilitating data-driven healthcare advancements and ensuring stringent data privacy safeguards is imperative t%li%foster trust among stakeholders and encourage the widespread adoption of genomic cancer panels. Addressing these concerns is critical t%li%realizing the full potential of genomic data in advancing precision medicine and personalized cancer care.
Limited Access t%li%Comprehensive Databases
Limited access t%li%comprehensive databases poses a significant challenge t%li%the Global Genomic Cancer Panel & Profiling Market. The success of precision medicine relies heavily on vast and diverse datasets that encompass genomic and clinical information from a wide range of populations and cancer types. However, the availability of such comprehensive databases is often constrained. Access t%li%extensive datasets is crucial for identifying patterns, understanding the genetic basis of cancers, and discovering relevant biomarkers that can inform personalized treatment strategies. The challenge arises due t%li%factors like restricted sharing of genomic data, varying data protection regulations, and the lack of standardized data-sharing frameworks. Building inclusive and representative databases becomes particularly challenging for rare cancers and underrepresented populations.
These limitations hinder the ability t%li%draw meaningful conclusions from genomic profiling, potentially leaving gaps in our understanding of the genetic intricacies of certain cancers. Efforts t%li%address this challenge involve fostering collaboration among researchers, healthcare institutions, and biotechnology companies t%li%promote the sharing of data while adhering t%li%ethical and legal considerations. Encouraging open data-sharing practices and establishing frameworks that ensure privacy and security can contribute t%li%overcoming the hurdle of limited access t%li%comprehensive databases, unlocking the full potential of genomic cancer panels in advancing precision oncology.
Key Market Trends
Rising Emphasis on Early Detection
The Global Genomic Cancer Panel & Profiling Market is witnessing a rising emphasis on early detection, marking a transformative shift in cancer care. Genomic cancer panels play a pivotal role in this paradigm by enabling the identification of genetic alterations associated with cancer at its incipient stages. Early detection through genomic profiling allows for the identification of specific biomarkers indicative of cancer predisposition or the presence of minimal residual disease. This emphasis on early detection aligns with the broader goal of intervening in cancer progression at its earliest, most treatable phases. Genomic cancer panels contribute t%li%precision oncology by uncovering genetic signatures that may indicate a predisposition t%li%certain cancers, enabling proactive screening and surveillance strategies.
The identification of actionable mutations early on facilitates the selection of targeted therapies, potentially improving treatment efficacy and patient outcomes. As healthcare systems increasingly recognize the value of early detection in reducing the burden of cancer, the adoption of genomic cancer panels for screening and early intervention is expected t%li%rise, shaping a future where personalized, genomic-driven approaches contribute significantly t%li%cancer prevention and early-stage management.
Segmental Insights
Tissue Testing Insights
Based on Tissue Testing, the Liquid tissue testing emerged as the fastest growing segment in the global genomic cancer panel and profiling market, especially for tissue testing. This trend signifies a shift towards utilizing liquid samples for testing, rather than traditional approaches, which is anticipated t%li%gain prominence in cancer diagnosis and treatment. Liquid biopsy techniques, such as the analysis of circulating tumor DNA (ctDNA), offer non-invasive and real-time monitoring of cancer-related genetic changes. This approach is valuable for early detection, treatment monitoring, and assessing minimal residual disease. As liquid tissue testing continues t%li%gain traction, it is expected t%li%play a crucial role in enhancing our understanding of cancer biology and improving patient outcomes through personalized treatment strategies.
Cancer Type Insights
Based on cancer type, the lung cancer segment dominated the Global Genomic Cancer Panel & Profiling Market in 2023. This is ascribed due t%li%its high prevalence and the critical role of genomic profiling in personalized treatment. As the leading cause of cancer-related deaths, lung cancer demands precise molecular analysis for targeted therapies. Genomic panels help identify specific mutations, guiding clinicians in selecting tailored treatments and improving patient outcomes. The increasing awareness of genomic testing benefits in lung cancer management, coupled with advancements in precision medicine, amplifies the prominence of lung cancer within the Genomic Cancer Panel & Profiling market, emphasizing the significance of genomic insights in optimizing therapeutic strategies for this prevalent and challenging malignancy.
Regional Insights
The dominance of the North America segment in the global Genomic Cancer Panel & Profiling Market is underpinned by several key factors. With a robust healthcare infrastructure and advanced research facilities, the region fosters the widespread adoption of genomic cancer profiling technologies. The presence of leading market players and increased investment in research and development initiatives further contribute t%li%the region's leadership position.
A higher prevalence of cancer cases in North America, combined with a proactive approach towards early detection and personalized medicine, drives the demand for genomic cancer panels. The collaborative efforts among research institutions, pharmaceutical companies, and healthcare providers in the region play a pivotal role in enhancing the market's growth trajectory. These collective endeavors solidify North America's dominant position on the global stage of genomic cancer panel and profiling, shaping the landscape of cancer diagnostics and treatment strategies worldwide.
Key Market Players
In this report, the Global Genomic Cancer Panel & Profiling Market has been segmented int%li%the following categories, in addition t%li%the industry trends which have als%li%been detailed below:
Company Profiles: Detailed analysis of the major companies presents in the Global Genomic Cancer Panel & Profiling Market.
Available Customizations:
Global Genomic Cancer Panel & Profiling Market report with the given market data, Tech Sci Research offers customizations according t%li%a company's specific needs. The following customization options are available for the report:
Company Information
The incorporation of artificial intelligence and machine learning augments the interpretation of intricate genomic data, facilitating more precise and expedited insights. Collaborations between biotechnology firms and research institutions drive innovation and the creation of comprehensive genomic profiling solutions. These partnerships advance the comprehension of cancer biology and aid in identifying novel therapeutic targets. The market witnesses a shift towards liquid biopsy approaches, enabling non-invasive and real-time monitoring of cancer-related genetic alterations. Liquid biopsy techniques, such as the examination of circulating tumor DNA (ctDNA), contribute t%li%early detection, treatment monitoring, and the evaluation of minimal residual disease.
Furthermore, the trend towards multi-omic integration, which merges genomic data with transcriptomics, proteomics, and other -omics information, offers a holistic perspective of cancer biology. This integrated approach enhances the identification of biomarkers and potential therapeutic targets, fostering a more thorough understanding of the complex molecular mechanisms underlying different cancer types. As the global healthcare landscape increasingly prioritizes personalized and targeted therapies, the Genomic Cancer Panel & Profiling Market is poised for further growth, delivering innovative solutions for precise cancer diagnostics and treatment decision-making. The continuous evolution of genomic technologies and their applications underscores the market's dynamic nature in advancing the era of personalized oncology.
Key Market Drivers
Advancements in Genomic Technologies
Advancements in genomic technologies have been instrumental in shaping the landscape of the Global Genomic Cancer Panel & Profiling Market, ushering in a new era of precision medicine. Next-Generation Sequencing (NGS) stands as a cornerstone in these advancements, revolutionizing the speed, efficiency, and depth of genomic analysis. The continuous evolution of NGS platforms has enabled researchers and clinicians t%li%conduct comprehensive genomic profiling with unprecedented accuracy and scale. Improved sequencing speed and reduced costs have made genomic profiling more accessible, allowing for the analysis of a broader range of genes and facilitating a deeper understanding of cancer-related genetic alterations. Beyond NGS, other genomic technologies such as microarray-based platforms and digital PCR contribute valuable insights. Microarrays provide a high-throughput method for simultaneously examining the expression levels of multiple genes, aiding in the identification of biomarkers associated with specific cancers.
Digital PCR offers enhanced sensitivity in detecting rare genetic mutations, contributing t%li%the precision of genomic profiling. The integration of artificial intelligence (AI) and machine learning (ML) has emerged as a transformative force in genomic data interpretation. Advanced algorithms analyze vast datasets, helping identify patterns, predict treatment responses, and discover novel genetic markers. This fusion of genomic technologies and AI not only accelerates the analysis process but als%li%enhances the accuracy of identifying clinically relevant genomic alterations. The advent of single-cell genomics represents another breakthrough, allowing researchers t%li%analyze individual cells within a heterogeneous tumor. This technology unveils the intra-tumor heterogeneity and provides a more nuanced understanding of the genetic diversity present in cancers. These collective advancements empower the Genomic Cancer Panel & Profiling Market t%li%offer more comprehensive and precise insights int%li%the genomic landscape of cancers. As these technologies continue t%li%evolve, the market is poised t%li%witness further refinement in diagnostic accuracy, therapeutic decision-making, and the realization of personalized treatment strategies for cancer patients globally.
Rising Cancer Incidence
The Global Genomic Cancer Panel & Profiling Market is significantly influenced by the alarming and escalating incidence of cancer worldwide. The pervasive rise in cancer cases serves as a driving force behind the increasing adoption of genomic technologies for comprehensive cancer profiling. Cancer remains a leading cause of morbidity and mortality globally, with new cases diagnosed each year reaching staggering numbers. This surge in cancer incidence intensifies the need for precise diagnostic tools that can unravel the intricate genetic underpinnings of various cancer types. Genomic cancer panels play a pivotal role in this scenari%li%by offering a systematic approach t%li%analyze the genetic alterations associated with specific cancers. As the diversity of cancer types expands, s%li%does the demand for tailored genomic profiling solutions. The ability of genomic technologies, such as Next-Generation Sequencing (NGS), t%li%analyze a multitude of genes simultaneously provides clinicians with a comprehensive view of the genomic landscape, aiding in the identification of key mutations, copy number variations, and other genetic abnormalities driving cancer progression.
The rising cancer incidence not only emphasizes the urgency for accurate and early diagnosis but als%li%underscores the importance of personalized treatment strategies. Genomic profiling enables clinicians t%li%identify specific genetic markers that guide the selection of targeted therapies, contributing t%li%more effective and tailored interventions. The exploration of new and emerging biomarkers associated with different cancer types is fueled by the need t%li%understand the molecular intricacies of each case, further amplifying the relevance and demand for genomic cancer panels. In conclusion, the relentless increase in cancer incidence acts as a catalyst for the Global Genomic Cancer Panel & Profiling Market, driving advancements in genomic technologies and fostering a paradigm shift towards precision medicine in the fight against cancer.
Precision Medicine Initiatives
Precision medicine initiatives are playing a pivotal role in shaping the trajectory of the Global Genomic Cancer Panel & Profiling Market, ushering in an era of personalized and targeted therapeutic approaches. These initiatives are driven by the recognition that each patient's cancer is unique, necessitating tailored treatment strategies based on the individual's genetic makeup. Genomic cancer panels stand at the forefront of this paradigm shift, enabling comprehensive analysis of the molecular alterations within a patient's tumor. The core principle of precision medicine is t%li%match specific genomic aberrations with targeted therapies, optimizing treatment outcomes and minimizing adverse effects. As genomic technologies, particularly Next-Generation Sequencing (NGS), become more sophisticated and accessible, precision medicine initiatives gain momentum. Clinicians leverage genomic cancer panels t%li%identify key genetic mutations, copy number variations, and other alterations that drive cancer progression.
This information becomes crucial for making informed decisions about the most effective therapies for a particular patient. These initiatives are often part of large-scale collaborative efforts involving healthcare institutions, research organizations, and biotechnology companies. The goal is t%li%create extensive databases of genomic and clinical data, facilitating a deeper understanding of the genetic basis of cancer and refining treatment strategies. The integration of artificial intelligence and machine learning further enhances the interpretation of vast datasets, assisting clinicians in identifying relevant biomarkers and predicting treatment responses. Precision medicine initiatives contribute t%li%the shift from a one-size-fits-all approach t%li%cancer treatment t%li%a more nuanced and individualized methodology. By aligning treatment plans with the specific genomic profile of each patient's cancer, these initiatives not only improve therapeutic efficacy but als%li%pave the way for future advancements in oncology. The Global Genomic Cancer Panel & Profiling Market is intricately linked t%li%the success and expansion of precision medicine initiatives, as they collectively drive innovation and bring about transformative changes in cancer care.
Key Market Challenges
Data Privacy and Security Concerns
Data privacy and security concerns constitute significant challenges within the Global Genomic Cancer Panel & Profiling Market. The extensive generation, storage, and sharing of genomic data raise crucial issues regarding patient confidentiality and protection. Genomic information is inherently sensitive, encompassing an individual's unique genetic makeup and potential predispositions t%li%various health conditions, including cancer. Securing genomic data from unauthorized access, breaches, or misuse is paramount. The fear of data breaches and the potential misuse of this highly personal information contribute t%li%concerns among patients, healthcare providers, and regulatory bodies.
The need t%li%comply with stringent data protection regulations, such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States or the General Data Protection Regulation (GDPR) in Europe, adds an additional layer of complexity. The challenge lies in establishing robust and standardized security measures t%li%safeguard genomic data throughout its lifecycle—from collection and storage t%li%transmission and analysis. Implementing encryption, access controls, and secure data sharing protocols becomes essential. Striking a balance between facilitating data-driven healthcare advancements and ensuring stringent data privacy safeguards is imperative t%li%foster trust among stakeholders and encourage the widespread adoption of genomic cancer panels. Addressing these concerns is critical t%li%realizing the full potential of genomic data in advancing precision medicine and personalized cancer care.
Limited Access t%li%Comprehensive Databases
Limited access t%li%comprehensive databases poses a significant challenge t%li%the Global Genomic Cancer Panel & Profiling Market. The success of precision medicine relies heavily on vast and diverse datasets that encompass genomic and clinical information from a wide range of populations and cancer types. However, the availability of such comprehensive databases is often constrained. Access t%li%extensive datasets is crucial for identifying patterns, understanding the genetic basis of cancers, and discovering relevant biomarkers that can inform personalized treatment strategies. The challenge arises due t%li%factors like restricted sharing of genomic data, varying data protection regulations, and the lack of standardized data-sharing frameworks. Building inclusive and representative databases becomes particularly challenging for rare cancers and underrepresented populations.
These limitations hinder the ability t%li%draw meaningful conclusions from genomic profiling, potentially leaving gaps in our understanding of the genetic intricacies of certain cancers. Efforts t%li%address this challenge involve fostering collaboration among researchers, healthcare institutions, and biotechnology companies t%li%promote the sharing of data while adhering t%li%ethical and legal considerations. Encouraging open data-sharing practices and establishing frameworks that ensure privacy and security can contribute t%li%overcoming the hurdle of limited access t%li%comprehensive databases, unlocking the full potential of genomic cancer panels in advancing precision oncology.
Key Market Trends
Rising Emphasis on Early Detection
The Global Genomic Cancer Panel & Profiling Market is witnessing a rising emphasis on early detection, marking a transformative shift in cancer care. Genomic cancer panels play a pivotal role in this paradigm by enabling the identification of genetic alterations associated with cancer at its incipient stages. Early detection through genomic profiling allows for the identification of specific biomarkers indicative of cancer predisposition or the presence of minimal residual disease. This emphasis on early detection aligns with the broader goal of intervening in cancer progression at its earliest, most treatable phases. Genomic cancer panels contribute t%li%precision oncology by uncovering genetic signatures that may indicate a predisposition t%li%certain cancers, enabling proactive screening and surveillance strategies.
The identification of actionable mutations early on facilitates the selection of targeted therapies, potentially improving treatment efficacy and patient outcomes. As healthcare systems increasingly recognize the value of early detection in reducing the burden of cancer, the adoption of genomic cancer panels for screening and early intervention is expected t%li%rise, shaping a future where personalized, genomic-driven approaches contribute significantly t%li%cancer prevention and early-stage management.
Segmental Insights
Tissue Testing Insights
Based on Tissue Testing, the Liquid tissue testing emerged as the fastest growing segment in the global genomic cancer panel and profiling market, especially for tissue testing. This trend signifies a shift towards utilizing liquid samples for testing, rather than traditional approaches, which is anticipated t%li%gain prominence in cancer diagnosis and treatment. Liquid biopsy techniques, such as the analysis of circulating tumor DNA (ctDNA), offer non-invasive and real-time monitoring of cancer-related genetic changes. This approach is valuable for early detection, treatment monitoring, and assessing minimal residual disease. As liquid tissue testing continues t%li%gain traction, it is expected t%li%play a crucial role in enhancing our understanding of cancer biology and improving patient outcomes through personalized treatment strategies.
Cancer Type Insights
Based on cancer type, the lung cancer segment dominated the Global Genomic Cancer Panel & Profiling Market in 2023. This is ascribed due t%li%its high prevalence and the critical role of genomic profiling in personalized treatment. As the leading cause of cancer-related deaths, lung cancer demands precise molecular analysis for targeted therapies. Genomic panels help identify specific mutations, guiding clinicians in selecting tailored treatments and improving patient outcomes. The increasing awareness of genomic testing benefits in lung cancer management, coupled with advancements in precision medicine, amplifies the prominence of lung cancer within the Genomic Cancer Panel & Profiling market, emphasizing the significance of genomic insights in optimizing therapeutic strategies for this prevalent and challenging malignancy.
Regional Insights
The dominance of the North America segment in the global Genomic Cancer Panel & Profiling Market is underpinned by several key factors. With a robust healthcare infrastructure and advanced research facilities, the region fosters the widespread adoption of genomic cancer profiling technologies. The presence of leading market players and increased investment in research and development initiatives further contribute t%li%the region's leadership position.
A higher prevalence of cancer cases in North America, combined with a proactive approach towards early detection and personalized medicine, drives the demand for genomic cancer panels. The collaborative efforts among research institutions, pharmaceutical companies, and healthcare providers in the region play a pivotal role in enhancing the market's growth trajectory. These collective endeavors solidify North America's dominant position on the global stage of genomic cancer panel and profiling, shaping the landscape of cancer diagnostics and treatment strategies worldwide.
Key Market Players
- Agilent Technologies, Inc
- ARUP Laboratories Inc
- Burning Rock Biotech Limited
- U.S. Caris MPI, Inc.
- Danaher Corporation
- Exact Sciences Corporation
- F. Hoffmann-La Roche Ltd
- Fulgent Genetics Inc.
- Illumina, Inc.
- Therm%li%Fisher Scientific Inc.
In this report, the Global Genomic Cancer Panel & Profiling Market has been segmented int%li%the following categories, in addition t%li%the industry trends which have als%li%been detailed below:
- Genomic Cancer Panel & Profiling Market, By Tissue Testing:
- Solid Tissue Testing
- Liquid Tissue Testing
- Genomic Cancer Panel & Profiling Market, By Cancer Panel Type:
- Single-Gene Panel
- Multi-Gene Panel
- Genomic Cancer Panel & Profiling Market, By Cancer Type:
- Lung Cancer
- Breast Cancer
- Colon Cancer
- Prostate Cancer
- Others
- Genomic Cancer Panel & Profiling Market, By Application:
- Clinical
- Research
- Genomic Cancer Panel & Profiling Market, By Technology:
- Next-Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Fluorescence In-Situ Hybridization (FISH)
- Immunohistochemistry (IHC)
- Others
- Genomic Cancer Panel & Profiling Market, By End-User:
- Hospitals
- Clinical and Diagnostic Laboratories
- Others
- Genomic Cancer Panel & Profiling Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Egypt
Company Profiles: Detailed analysis of the major companies presents in the Global Genomic Cancer Panel & Profiling Market.
Available Customizations:
Global Genomic Cancer Panel & Profiling Market report with the given market data, Tech Sci Research offers customizations according t%li%a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up t%li%five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Tissue Testing (Solid Tissue Testing, Liquid Tissue Testing)
5.2.2. By Cancer Panel Type (Single-Gene Panel, Multi-Gene Panel)
5.2.3. By Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, Prostate Cancer, Others)
5.2.4. By Application (Clinical, Research)
5.2.5. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
5.2.6. By End-User (Hospitals, Clinical and Diagnostic Laboratories, Others)
5.2.7. By Region
5.2.8. By Company (2023)
5.3. Market Map
5.3.1. By Tissue Testing
5.3.2. By Cancer Panel Type
5.3.3. By Cancer Type
5.3.4. By Application
5.3.5. By Technology
5.3.6. By End-User
5.3.7. By Region
6. ASIA PACIFIC GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Tissue Testing
6.2.2. By Cancer Panel Type
6.2.3. By Cancer Type
6.2.4. By Application
6.2.5. By Technology
6.2.6. By End-User
6.2.7. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Genomic Cancer Panel & Profiling Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Tissue Testing
6.3.1.2.2. By Cancer Panel Type
6.3.1.2.3. By Cancer Type
6.3.1.2.4. By Application
6.3.1.2.5. By Technology
6.3.1.2.6. By End-User
6.3.2. India Genomic Cancer Panel & Profiling Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Tissue Testing
6.3.2.2.2. By Cancer Panel Type
6.3.2.2.3. By Cancer Type
6.3.2.2.4. By Application
6.3.2.2.5. By Technology
6.3.2.2.6. By End-User
6.3.3. Australia Genomic Cancer Panel & Profiling Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Tissue Testing
6.3.3.2.2. By Cancer Panel Type
6.3.3.2.3. By Cancer Type
6.3.3.2.4. By Application
6.3.3.2.5. By Technology
6.3.3.2.6. By End-User
6.3.4. Japan Genomic Cancer Panel & Profiling Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Tissue Testing
6.3.4.2.2. By Cancer Panel Type
6.3.4.2.3. By Cancer Type
6.3.4.2.4. By Application
6.3.4.2.5. By Technology
6.3.4.2.6. By End-User
6.3.5. South Korea Genomic Cancer Panel & Profiling Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Tissue Testing
6.3.5.2.2. By Cancer Panel Type
6.3.5.2.3. By Cancer Type
6.3.5.2.4. By Application
6.3.5.2.5. By Technology
6.3.5.2.6. By End-User
7. EUROPE GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Tissue Testing
7.2.2. By Cancer Panel Type
7.2.3. By Cancer Type
7.2.4. By Application
7.2.5. By Technology
7.2.6. By End-User
7.2.7. By Country
7.3. Europe: Country Analysis
7.3.1. France Genomic Cancer Panel & Profiling Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Tissue Testing
7.3.1.2.2. By Cancer Panel Type
7.3.1.2.3. By Cancer Type
7.3.1.2.4. By Application
7.3.1.2.5. By Technology
7.3.1.2.6. By End-User
7.3.2. Germany Genomic Cancer Panel & Profiling Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Tissue Testing
7.3.2.2.2. By Cancer Panel Type
7.3.2.2.3. By Cancer Type
7.3.2.2.4. By Application
7.3.2.2.5. By Technology
7.3.2.2.6. By End-User
7.3.3. Spain Genomic Cancer Panel & Profiling Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Tissue Testing
7.3.3.2.2. By Cancer Panel Type
7.3.3.2.3. By Cancer Type
7.3.3.2.4. By Application
7.3.3.2.5. By Technology
7.3.3.2.6. By End-User
7.3.4. Italy Genomic Cancer Panel & Profiling Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Tissue Testing
7.3.4.2.2. By Cancer Panel Type
7.3.4.2.3. By Cancer Type
7.3.4.2.4. By Application
7.3.4.2.5. By Technology
7.3.4.2.6. By End-User
7.3.5. United Kingdom Genomic Cancer Panel & Profiling Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Tissue Testing
7.3.5.2.2. By Cancer Panel Type
7.3.5.2.3. By Cancer Type
7.3.5.2.4. By Application
7.3.5.2.5. By Technology
7.3.5.2.6. By End-User
8. NORTH AMERICA GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Tissue Testing
8.2.2. By Cancer Panel Type
8.2.3. By Cancer Type
8.2.4. By Application
8.2.5. By Technology
8.2.6. By End-User
8.2.6. By Country
8.3. North America: Country Analysis
8.3.1. United States Genomic Cancer Panel & Profiling Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Tissue Testing
8.3.1.2.2. By Cancer Panel Type
8.3.1.2.3. By Cancer Type
8.3.1.2.4. By Application
8.3.1.2.5. By Technology
8.3.1.2.6. By End-User
8.3.2. Mexico Genomic Cancer Panel & Profiling Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Tissue Testing
8.3.2.2.2. By Cancer Panel Type
8.3.2.2.3. By Cancer Type
8.3.2.2.4. By Application
8.3.2.2.5. By Technology
8.3.2.2.6. By End-User
8.3.3. Canada Genomic Cancer Panel & Profiling Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Tissue Testing
8.3.3.2.2. By Cancer Panel Type
8.3.3.2.3. By Cancer Type
8.3.3.2.4. By Application
8.3.3.2.5. By Technology
8.3.3.2.6. By End-User
9. SOUTH AMERICA GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Tissue Testing
9.2.2. By Cancer Panel Type
9.2.3. By Cancer Type
9.2.4. By Application
9.2.5. By Technology
9.2.6. By End-User
9.2.7. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Genomic Cancer Panel & Profiling Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Tissue Testing
9.3.1.2.2. By Cancer Panel Type
9.3.1.2.3. By Cancer Type
9.3.1.2.4. By Application
9.3.1.2.5. By Technology
9.3.1.2.6. By End-User
9.3.2. Argentina Genomic Cancer Panel & Profiling Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Tissue Testing
9.3.2.2.2. By Cancer Panel Type
9.3.2.2.3. By Cancer Type
9.3.2.2.4. By Application
9.3.2.2.5. By Technology
9.3.2.2.6. By End-User
9.3.3. Colombia Genomic Cancer Panel & Profiling Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Tissue Testing
9.3.3.2.2. By Cancer Panel Type
9.3.3.2.3. By Cancer Type
9.3.3.2.4. By Application
9.3.3.2.5. By Technology
9.3.3.2.6. By End-User
10. MIDDLE EAST AND AFRICA GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Tissue Testing
10.2.2. By Cancer Panel Type
10.2.3. By Cancer Type
10.2.4. By Application
10.2.5. By Technology
10.2.6. By End-User
10.2.7. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Genomic Cancer Panel & Profiling Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Tissue Testing
10.3.1.2.2. By Cancer Panel Type
10.3.1.2.3. By Cancer Type
10.3.1.2.4. By Application
10.3.1.2.5. By Technology
10.3.1.2.6. By End-User
10.3.2. Saudi Arabia Genomic Cancer Panel & Profiling Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Tissue Testing
10.3.2.2.2. By Cancer Panel Type
10.3.2.2.3. By Cancer Type
10.3.2.2.4. By Application
10.3.2.2.5. By Technology
10.3.2.2.6. By End-User
10.3.3. UAE Genomic Cancer Panel & Profiling Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Tissue Testing
10.3.3.2.2. By Cancer Panel Type
10.3.3.2.3. By Cancer Type
10.3.3.2.4. By Application
10.3.3.2.5. By Technology
10.3.3.2.6. By End-User
10.3.4. Egypt Genomic Cancer Panel & Profiling Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Tissue Testing
10.3.4.2.2. By Cancer Panel Type
10.3.4.2.3. By Cancer Type
10.3.4.2.4. By Application
10.3.4.2.5. By Technology
10.3.4.2.6. By End-User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. GLOBAL GENOMIC CANCER PANEL & PROFILING MARKET: SWOT ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. COMPETITIVE LANDSCAPE
15.1. Agilent Technologies, Inc.
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (In case of listed)
15.1.5. Recent Developments
15.1.6. SWOT Analysis
15.2. ARUP Laboratories Inc
15.3. Burning Rock Biotech Limited
15.4. U.S. Caris MPI, Inc.
15.5. Danaher Corporation
15.6. Exact Sciences Corporation
15.7. F. Hoffmann-La Roche Ltd
15.8. Fulgent Genetics Inc.
15.9. Illumina, Inc.
15.10. Thermo Fisher Scientific Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Tissue Testing (Solid Tissue Testing, Liquid Tissue Testing)
5.2.2. By Cancer Panel Type (Single-Gene Panel, Multi-Gene Panel)
5.2.3. By Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, Prostate Cancer, Others)
5.2.4. By Application (Clinical, Research)
5.2.5. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
5.2.6. By End-User (Hospitals, Clinical and Diagnostic Laboratories, Others)
5.2.7. By Region
5.2.8. By Company (2023)
5.3. Market Map
5.3.1. By Tissue Testing
5.3.2. By Cancer Panel Type
5.3.3. By Cancer Type
5.3.4. By Application
5.3.5. By Technology
5.3.6. By End-User
5.3.7. By Region
6. ASIA PACIFIC GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Tissue Testing
6.2.2. By Cancer Panel Type
6.2.3. By Cancer Type
6.2.4. By Application
6.2.5. By Technology
6.2.6. By End-User
6.2.7. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Genomic Cancer Panel & Profiling Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Tissue Testing
6.3.1.2.2. By Cancer Panel Type
6.3.1.2.3. By Cancer Type
6.3.1.2.4. By Application
6.3.1.2.5. By Technology
6.3.1.2.6. By End-User
6.3.2. India Genomic Cancer Panel & Profiling Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Tissue Testing
6.3.2.2.2. By Cancer Panel Type
6.3.2.2.3. By Cancer Type
6.3.2.2.4. By Application
6.3.2.2.5. By Technology
6.3.2.2.6. By End-User
6.3.3. Australia Genomic Cancer Panel & Profiling Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Tissue Testing
6.3.3.2.2. By Cancer Panel Type
6.3.3.2.3. By Cancer Type
6.3.3.2.4. By Application
6.3.3.2.5. By Technology
6.3.3.2.6. By End-User
6.3.4. Japan Genomic Cancer Panel & Profiling Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Tissue Testing
6.3.4.2.2. By Cancer Panel Type
6.3.4.2.3. By Cancer Type
6.3.4.2.4. By Application
6.3.4.2.5. By Technology
6.3.4.2.6. By End-User
6.3.5. South Korea Genomic Cancer Panel & Profiling Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Tissue Testing
6.3.5.2.2. By Cancer Panel Type
6.3.5.2.3. By Cancer Type
6.3.5.2.4. By Application
6.3.5.2.5. By Technology
6.3.5.2.6. By End-User
7. EUROPE GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Tissue Testing
7.2.2. By Cancer Panel Type
7.2.3. By Cancer Type
7.2.4. By Application
7.2.5. By Technology
7.2.6. By End-User
7.2.7. By Country
7.3. Europe: Country Analysis
7.3.1. France Genomic Cancer Panel & Profiling Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Tissue Testing
7.3.1.2.2. By Cancer Panel Type
7.3.1.2.3. By Cancer Type
7.3.1.2.4. By Application
7.3.1.2.5. By Technology
7.3.1.2.6. By End-User
7.3.2. Germany Genomic Cancer Panel & Profiling Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Tissue Testing
7.3.2.2.2. By Cancer Panel Type
7.3.2.2.3. By Cancer Type
7.3.2.2.4. By Application
7.3.2.2.5. By Technology
7.3.2.2.6. By End-User
7.3.3. Spain Genomic Cancer Panel & Profiling Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Tissue Testing
7.3.3.2.2. By Cancer Panel Type
7.3.3.2.3. By Cancer Type
7.3.3.2.4. By Application
7.3.3.2.5. By Technology
7.3.3.2.6. By End-User
7.3.4. Italy Genomic Cancer Panel & Profiling Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Tissue Testing
7.3.4.2.2. By Cancer Panel Type
7.3.4.2.3. By Cancer Type
7.3.4.2.4. By Application
7.3.4.2.5. By Technology
7.3.4.2.6. By End-User
7.3.5. United Kingdom Genomic Cancer Panel & Profiling Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Tissue Testing
7.3.5.2.2. By Cancer Panel Type
7.3.5.2.3. By Cancer Type
7.3.5.2.4. By Application
7.3.5.2.5. By Technology
7.3.5.2.6. By End-User
8. NORTH AMERICA GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Tissue Testing
8.2.2. By Cancer Panel Type
8.2.3. By Cancer Type
8.2.4. By Application
8.2.5. By Technology
8.2.6. By End-User
8.2.6. By Country
8.3. North America: Country Analysis
8.3.1. United States Genomic Cancer Panel & Profiling Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Tissue Testing
8.3.1.2.2. By Cancer Panel Type
8.3.1.2.3. By Cancer Type
8.3.1.2.4. By Application
8.3.1.2.5. By Technology
8.3.1.2.6. By End-User
8.3.2. Mexico Genomic Cancer Panel & Profiling Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Tissue Testing
8.3.2.2.2. By Cancer Panel Type
8.3.2.2.3. By Cancer Type
8.3.2.2.4. By Application
8.3.2.2.5. By Technology
8.3.2.2.6. By End-User
8.3.3. Canada Genomic Cancer Panel & Profiling Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Tissue Testing
8.3.3.2.2. By Cancer Panel Type
8.3.3.2.3. By Cancer Type
8.3.3.2.4. By Application
8.3.3.2.5. By Technology
8.3.3.2.6. By End-User
9. SOUTH AMERICA GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Tissue Testing
9.2.2. By Cancer Panel Type
9.2.3. By Cancer Type
9.2.4. By Application
9.2.5. By Technology
9.2.6. By End-User
9.2.7. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Genomic Cancer Panel & Profiling Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Tissue Testing
9.3.1.2.2. By Cancer Panel Type
9.3.1.2.3. By Cancer Type
9.3.1.2.4. By Application
9.3.1.2.5. By Technology
9.3.1.2.6. By End-User
9.3.2. Argentina Genomic Cancer Panel & Profiling Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Tissue Testing
9.3.2.2.2. By Cancer Panel Type
9.3.2.2.3. By Cancer Type
9.3.2.2.4. By Application
9.3.2.2.5. By Technology
9.3.2.2.6. By End-User
9.3.3. Colombia Genomic Cancer Panel & Profiling Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Tissue Testing
9.3.3.2.2. By Cancer Panel Type
9.3.3.2.3. By Cancer Type
9.3.3.2.4. By Application
9.3.3.2.5. By Technology
9.3.3.2.6. By End-User
10. MIDDLE EAST AND AFRICA GENOMIC CANCER PANEL & PROFILING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Tissue Testing
10.2.2. By Cancer Panel Type
10.2.3. By Cancer Type
10.2.4. By Application
10.2.5. By Technology
10.2.6. By End-User
10.2.7. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Genomic Cancer Panel & Profiling Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Tissue Testing
10.3.1.2.2. By Cancer Panel Type
10.3.1.2.3. By Cancer Type
10.3.1.2.4. By Application
10.3.1.2.5. By Technology
10.3.1.2.6. By End-User
10.3.2. Saudi Arabia Genomic Cancer Panel & Profiling Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Tissue Testing
10.3.2.2.2. By Cancer Panel Type
10.3.2.2.3. By Cancer Type
10.3.2.2.4. By Application
10.3.2.2.5. By Technology
10.3.2.2.6. By End-User
10.3.3. UAE Genomic Cancer Panel & Profiling Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Tissue Testing
10.3.3.2.2. By Cancer Panel Type
10.3.3.2.3. By Cancer Type
10.3.3.2.4. By Application
10.3.3.2.5. By Technology
10.3.3.2.6. By End-User
10.3.4. Egypt Genomic Cancer Panel & Profiling Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Tissue Testing
10.3.4.2.2. By Cancer Panel Type
10.3.4.2.3. By Cancer Type
10.3.4.2.4. By Application
10.3.4.2.5. By Technology
10.3.4.2.6. By End-User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. GLOBAL GENOMIC CANCER PANEL & PROFILING MARKET: SWOT ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. COMPETITIVE LANDSCAPE
15.1. Agilent Technologies, Inc.
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (In case of listed)
15.1.5. Recent Developments
15.1.6. SWOT Analysis
15.2. ARUP Laboratories Inc
15.3. Burning Rock Biotech Limited
15.4. U.S. Caris MPI, Inc.
15.5. Danaher Corporation
15.6. Exact Sciences Corporation
15.7. F. Hoffmann-La Roche Ltd
15.8. Fulgent Genetics Inc.
15.9. Illumina, Inc.
15.10. Thermo Fisher Scientific Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
